Education
About Us
Working with TipRanks
Follow Us
BioNexus Gene Lab Corp (BGLC)
NASDAQ:BGLC
Total Valuation
BioNexus Gene Lab Corp has a market cap or net worth of $4.98M. The enterprise value is $189.31M.
Market Cap$4.98M
Enterprise Value$189.31M
Share Statistics
BioNexus Gene Lab Corp has 1,796,597 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,796,597
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioNexus Gene Lab Corp’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -18.37%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.15
Return on Invested Capital (ROIC)-18.37%
Return on Capital Employed (ROCE)-0.19
Revenue Per Employee317.02K
Profits Per Employee-53.28K
Employee Count30
Asset Turnover0.91
Inventory Turnover5.92
Valuation Ratios
The current PE Ratio of BioNexus Gene Lab Corp is -31.21. BioNexus Gene Lab Corp’s PEG ratio is 3.14.
PE Ratio-31.21
PS Ratio0.00
PB Ratio24.65
Price to Fair Value5.99
Price to FCF335.34
Price to Operating Cash Flow301.95
PEG Ratio3.14
Income Statement
In the last 12 months, BioNexus Gene Lab Corp had revenue of 9.51M and earned -1.60M in profits. Earnings per share was -0.09.
Revenue9.51M
Gross Profit1.29M
Operating Income-1.57M
Pretax Income-1.59M
Net Income-1.60M
EBITDA-1.42M
Earnings Per Share (EPS)-0.09
Cash Flow
In the last 12 months, operating cash flow was -3.02M and capital expenditures -205.04K, giving a free cash flow of -3.22M billion.
Operating Cash Flow-3.02M
Free Cash Flow-3.22M
Free Cash Flow per Share-1.79
Dividends & Yields
BioNexus Gene Lab Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.31
52-Week Price Change-41.06%
50-Day Moving Average2.96
200-Day Moving Average3.30
Relative Strength Index (RSI)45.34
Average Volume (3m)93.92K
Important Dates
BioNexus Gene Lab Corp upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
BioNexus Gene Lab Corp as a current ratio of 3.81, with Debt / Equity ratio of 0.85%
Current Ratio3.81
Quick Ratio3.10
Debt to Market Cap<0.01
Net Debt to EBITDA2.93
Interest Coverage Ratio-74.42
Taxes
In the past 12 months, BioNexus Gene Lab Corp has paid 3.49K in taxes.
Income Tax3.49K
Effective Tax Rate>-0.01
Enterprise Valuation
BioNexus Gene Lab Corp EV to EBITDA ratio is -32.19, with an EV/FCF ratio of -18.58.
EV to Sales4.81
EV to EBITDA-32.19
EV to Free Cash Flow-18.58
EV to Operating Cash Flow-20.47
Balance Sheet
BioNexus Gene Lab Corp has $1.09M in cash and marketable securities with $200.11K in debt, giving a net cash position of -$891.09K billion.
Cash & Marketable Securities$1.09M
Total Debt$200.11K
Net Cash-$891.09K
Net Cash Per Share-$0.50
Tangible Book Value Per Share$0.47
Margins
Gross margin is 11.52%, with operating margin of -16.55%, and net profit margin of -16.81%.
Gross Margin11.52%
Operating Margin-16.55%
Pretax Margin-16.77%
Net Profit Margin-16.81%
EBITDA Margin-14.94%
EBIT Margin-16.55%
Analyst Forecast
The average price target for BioNexus Gene Lab Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―